BIZ DESK
Lupin’s share price slipped to a seven-week low, dropping over 5% to an intra-day low of ₹2,235 on the BSE (AROUN 1 PM). The sharp downward pressure extended the pharmaceutical stock’s two-day losing streak to approximately 5%, heavily underperforming wider market benchmarks where the BSE Sensex and BSE Healthcare index displayed relative resilience.
Key Market Performance Metrics
- Intra-Day Low: ₹2,235 (down 5.22%)
- Monthly Trend: The stock corrected roughly 9% over the past month, trailing the BSE Sensex’s 1.4% gain and the BSE Healthcare index’s 2.6% rally.
- Quarterly Trend: Over a three-month horizon, Lupin holds a modest gain of 3%, significantly lagging behind the broader Healthcare index’s 20% surge.
Contextual Drivers: Earnings and US Outlook
The downward movement follows the release of Lupin’s Q1 FY27 financial results and management commentary:
- Record Revenues:Lupin reported crossing ₹8,000 crore in quarterly operational revenue for the first time in its history, alongside a 16% rise in net profit to ₹1,415 crore.
- The Earnings Caveat:Despite record top-line growth and a 50% year-on-year surge in EBITDA (exceeding ₹2,400 crore), net income margins faced slight compression due to higher operating expenses.
- Cautious US Guidance:Management issued a cautious outlook for the United States market—where Lupin maintains a strong #3 generic position—anticipating a temporary dip in quarterly US revenues to the $250–$280 million range due to mounting competitive pressures before a projected recovery in fiscal 2028. This cautious guidance, paired with cash outflows tied to recent strategic moves like the VISUfarma acquisition, has led to near-term profit-booking by investors.
Disclaimer: This article is a journalistic rehash prepared for business reporting purposes. It is not investment advice. Readers are advised to consult certified financial professionals before making investment decisions.